Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam

Journal of Tropical Pediatrics

Volumn 55, Issue 1, 2009, Pages 26-31

  Lang, Jean ^a   Feroldi, Emmanuel ^a   Vien, Nguyen Cong ^b  

^a SANOFI PASTEUR   (France)

^b Children's Hospital No 2   (Viet Nam)

Author keywords

Concomitant DTP IPV; Expanded Program of Immunization; Intramuscular; Purified Vero cell rabies vaccine; Rabies pre exposure immunization; Routine childhood vaccination

Indexed keywords

DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; POLIOMYELITIS VIRUS 1 ANTIBODY; POLIOMYELITIS VIRUS 2 ANTIBODY; POLIOMYELITIS VIRUS 3 ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; POLIOMYELITIS VACCINE;

ABSENCE OF SIDE EFFECTS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RABIES; VACCINATION; VERO CELL; VIET NAM; ANIMAL; CERCOPITHECUS; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOLOGY; PERTUSSIS; POLIOMYELITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; TETANUS;

ANIMALS; CERCOPITHECUS AETHIOPS; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; MALE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; PROSPECTIVE STUDIES; RABIES; RABIES VACCINES; RISK; TETANUS; VERO CELLS; VIETNAM; WHOOPING COUGH;

EID: 60749134427     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmm100     Document Type: Article

References (19)

1. Knobel DL, Cleaveland S, Coleman PG, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005;83:360-8.
2. Anonymous. WHO expert consultation on rabies. World Health Organ Tech Rep Ser 2005;931:1-88.
3. Pancharoen C, Thisyakorn U, Lawtongkum W, et al. Rabies exposures in Thai children. Wilderness Environ Med 2001;12:239-43.
4. Sriaroon C, Sriaroon P, Daviratanasilpa S, et al. Retrospective: animal attacks and rabies exposures in Thai children. Travel Med Infect Dis 2006;4:270-4.
5. Tepsumethanon S, Tepsumethanon V, Wilde H. Risk of rabies after mammal bites in Thai children. J Med Assoc Thai 2002;85:77-81.
6. Anonymous. Rabies vaccines. Wkly Epidemiol Rec 2002;77:109-19.
7. Miranda ME. Rabies epidemiology, epidemiology, disease burden and disease burden and vaccine utilization in Asia vaccine utilization in Asia. Presented at the National Institute of Allergy and Infectious Diseases (NIAID) meeting 'Vaccines for Viral Infections in Developing Countries', 27, 28 July, 2006, Yokohama, Japan; 2004.
8. Anonymous. Rabies vaccine-update. Wkly Epidemiol Rec 2007;82:62-8.
9. Dureux B, Canton P, Gerard A, et al. Rabies vaccine for human use, cultivated on Vero cells. Lancet 1986;2:98.
10. Jaiiaroensup W, Lang J, Thipkong P, et al. Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally (Results of a prospective randomized trial). Vaccine 1998;16:1559-62.
11. Lang J, Rongrre N, Plotkin S, et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 1997;349:1663-5.
12. Lang J, Hoa DQ, Gioi NV, et al. Booster vaccination at 1 year with a rabies vaccine associated with DTP-IPV in infants living in a rabies endemic country. J Trop Pediatr 1999;45:181-3.
13. Sabchareon A, Chantavanich P, Pasuralertsakul S, et al. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Pediatr Infect Dis J 1998;17:1001-7.
14. Strady A, Lang J, Lienard M, et al. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 1998;177:1290-5.
15. Suwansrinon K, Wilde H, Benjavongkulchai M, et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: A prospective study showing long lasting immunity. Vaccine 2006;24:3878-80.
16. Chulasugandha P, Khawplod P, Havanond P, et al. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 2006;24:1478-82.
17. Anonymous. World Health Organization: Administration of rabies immunoglobulin. http://www.whoint/rabies/human/adminimmuno/en/printhtml (20 March 2007, date last accessed).
18. Lang J, Duong QH, Gioi NV, et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunization session in Viet Nam: Results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999;93:208-13.
19. Goswami A, Plun-Favreau J, Nicoloyannis N, et al. The real cost of rabies post-exposure treatments. Vaccine 2005;23:2970-6.